Hormonal
Mitochondrial dysfunction is a necessary driver of the Senescence-Associated Secretory Phenotype (SASP), as evidenced by the elimination of SASP in cells devoid of mitochondria, while irreversible cell cycle arrest persists.
Aging and age-related inflammation are driven by dysfunctional mitochondria producing the SASP. Interventions that target mitochondrial health (e.g., senolytics, senostatics like rapamycin or metformin) may reduce this inflammatory burden. Focus on strategies that support mitochondrial quality control, such as exercise and metabolic health, rather than just energy output.
Using this tool we showed that senescent cells which contained no mitochondria had no SASP (both at protein and mRNA level) but still underwent the irreversible cell cycle arrest [71].
Why this rating
Based on a review of multiple studies including proof-of-principle experiments using PINK1/Parkin-induced mitophagy.
Source
Mitochondrial dysfunction and cell senescence: deciphering a complex relationship
James Chapman et al. · FEBS Letters · 2019
DOI 10.1002/1873-3468.13498
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →